Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, today announced that it will
present preclinical data from the BioJet™ Systemic Oral Delivery
Platform at the Next Gen Peptide Formulation & Delivery Summit,
which will take place June 18–20, 2024 in Boston.
Details of the presentation are as follows:
Presentation Title: |
Empowering
Peptide Self Administration with Needle-Free Smart Capsules |
Track: |
Pioneering Devices to Increase the Reach of Peptide APIs |
Date & Time: |
Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern time |
Presenting Author: |
Sharat Singh, PhD, Head of Research, Biora Therapeutics,
Inc. |
Dr. Singh will also participate in a panel discussion on June 19
at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery
& Formulation for Improved Bioavailability,” alongside
representatives from Eli Lilly, Merck, and Novo Nordisk.
Selections from the presentation will be made available on the
Biora Therapeutics website following the event.
About Sharat Singh, PhDSharat Singh brings over
25 years of experience as a dynamic and innovative scientific
leader to his role at Biora Therapeutics, where he is focused on
development of the company’s ingestible drug-device combination
product candidates. Dr. Singh previously held scientific leadership
roles at Aclara Biosciences, Prometheus Laboratories, and Nestle
Health Sciences, where he established partnerships with leading
biotech/pharmaceutical companies and conducted multiple phase I/II
clinical trials in both oncology and gastrointestinal disease. As
Chief Scientific Officer at Prometheus Laboratories, Sharat worked
on topical formulation of budesonide for both Crohn’s disease
(marketed as Endocort) and ulcerative colitis. He is the key
inventor of multiple platform technologies (CEER, ANSER, eTag, and
LOCI) and has authored over 100 patents. In his academic career,
Sharat conducted inter-disciplinary research as a postdoctoral
fellow at Columbia University. He holds a PhD in Chemistry from
IISc, Bangalore, and has authored over 100 manuscripts and
presentations.
About the BioJet™ Systemic Oral Delivery
PlatformBiora's BioJet systemic oral therapeutics platform
uses an ingestible capsule for needle-free, oral delivery of large
molecules designed to achieve systemic bioavailability and replace
injection for better management of chronic diseases.
The BioJet platform uses an ingestible device designed to
transit through the digestive system and activate in the small
intestine, where liquid jets deliver a drug directly into the small
intestine for uptake into systemic circulation. The BioJet device
is approximately the size of a multivitamin and is designed to
autonomously deliver a wide range of large molecules, such as
proteins, peptides, and nucleic acids, in liquid formulation at
multi-milligram doses, without requiring complex reformulation.
Biora holds a comprehensive patent position for the BioJet
systemic oral delivery platform, with approximately 12 issued
patents and 31 pending applications that cover its delivery
platform and methods for using the platform to treat a disease or
condition in a patient using liquid jet delivery of a wide range of
drugs.
About Biora TherapeuticsBiora Therapeutics is
reimagining therapeutic delivery. By creating innovative smart
pills designed for targeted drug delivery to the GI tract, and
systemic, needle-free delivery of biotherapeutics, the company is
developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms:
the NaviCap™ targeted oral delivery platform, which is designed to
improve outcomes for patients with inflammatory bowel disease
through treatment at the site of disease in the gastrointestinal
tract, and the BioJet™ systemic oral delivery platform, which is
designed to replace injection for better management of chronic
diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development, preclinical
and clinical trial activities, and partnering and collaboration
efforts with third parties, are forward-looking statements. In some
cases, you can identify forward-looking statements by terms such as
“may,” “might,” “will,” “objective,” “intend,” “should,” “could,”
“can,” “would,” “expect,” “anticipate,” “forward,” “believe,”
“design,” “estimate,” “predict,” “potential,” “plan,” “target,” or
the negative of these terms, and similar expressions intended to
identify forward-looking statements. These statements reflect our
plans, estimates, and expectations, as of the date of this press
release. These statements involve known and unknown risks,
uncertainties and other factors that could cause our actual results
to differ materially from the forward-looking statements expressed
or implied in this press release. Such risks, uncertainties, and
other factors include, among others, our ability to innovate in the
field of therapeutics, our ability to make future FDA filings and
initiate and execute clinical trials on expected timelines or at
all, our ability to obtain and maintain regulatory approval or
clearance of our products on expected timelines or at all, our
plans to research, develop, and commercialize new products, the
unpredictable relationship between preclinical study results and
clinical study results, our expectations regarding allowed patents
or intended grants to result in issued or granted patents, our
expectations regarding opportunities with current or future
pharmaceutical collaborators or partners, our ability to raise
sufficient capital to achieve our business objectives, and those
risks described in “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Annual Report on Form 10-K for the year ended December 31, 2023
filed with the SEC and other subsequent documents, including
Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com (646) 627-8390
Media Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Biora Therapeutics (NASDAQ:BIOR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024